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ness and cortical thickness should always be evaluated in 
relation to a child’s height and BA, especially around puber-
ty. The use of skeletal maturity, assessed on a radiograph 
alone to estimate chronological age for immigration author-
ities or criminal courts is not recommended. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Part 1 of this review dealt with the following themes: 
the negligible radiation dose involved in the hand-wrist 
radiograph required to assess bone maturation [also 
called skeletal maturity, or bone age (BA)], the various 
methods of assessment currently employed in clinical 
routine, and the use of such assessment in children with 
short stature of various etiologies. Part 2 deals with the 
use of bone maturation films in children with tall stature, 
precocious puberty (PP), congenital adrenal hyperplasia 
(CAH), skeletal dysplasias, and unknown chronological 
age, and with the possibility of using BA to evaluate bone 
mineral density and a possible secular trend.
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 Abstract 
 If height-limiting treatment is being considered for a child 
with tall stature, skeletal maturity is invaluable in the se-
lection of appropriate patients for treatment, determining 
appropriate age of treatment commencement, monitoring 
progress of treatment, and determining the expected treat-
ment effect on adult height. In precocious puberty, bone 
maturation can be usefully assessed at initial diagnosis and 
start of treatment and at regular intervals thereafter during 
treatment monitoring. Together with height, bone matura-
tion is an essential parameter for long-term treatment mon-
itoring in congenital adrenal hyperplasia. Bone age (BA) de-
termination in children with skeletal dysplasia is only feasible 
in a few disorders and estimations should be treated with 
caution. Radiographs of the left hand and wrist are, however, 
essential in the diagnosis of many skeletal disorders. Bone 
mineralization and measures of bone lengths, width, thick-
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 Tall Stature 
 In some countries, children with extreme tall stature 
have the (controversially discussed) option of treatment 
with sex steroids to accelerate epiphyseal fusion or of 
growth plate drilling to limit adult height. Bone matura-
tion estimates as a means to assess residual growth po-
tential is invaluable in the clinical and research situation 
regarding tall stature, for:
 (1) selection of appropriate patients for treatment, 
 (2) determining appropriate time for treatment com-
mencement, 
 (3) monitoring progress of treatment, and 
 (4) determination of treatment effect on adult height. 
 The relationship between bone maturation and height 
must be considered: tall children will be expected to have 
slightly advanced BA, in accordance with their ‘advance-
ment’ in height.
 In a comparison of adult height prediction methods 
used on children with tall stature, Joss et al.  [1] concluded 
that there is no best or most accurate method for predict-
ing adult height in tall children: both the Tanner-White-
house mark II and the Bayley-Pinneau method tend to 
overestimate adult height at various BAs, especially the 
Bayley-Pinneau method up to a bone maturation of 12 
‘years’ in boys and 14 ‘years’ in girls. Binder et al.  [2] found 
an overprediction of the Bayley-Pinneau method of only 
0.14 cm ( 8 3.10) in girls and of 1.86 cm ( 8 4.37) in boys.
 Early high-dose treatment with estrogen (for girls) or 
testosterone (for boys) was found to reduce adult height by 
between 2 and 10 cm in the mostly small follow-up studies 
between the 1950s and the 1990s, which were mainly 
based on bone maturation-derived height predictions.
 In a large retrospective Dutch study of girls who all 
had a predicted adult height above 181 cm, the total mean 
(SEM) reduction of adult height was 5.9 (0.2) 5.3 (0.1), and 
4.4 (0.2) cm when treated with 0.5, 0.25, and 0.1 mg ethi-
nyl estradiol per day, respectively. Group 1 (n = 263) was 
treated for 2.02 (0.03) years, group 2 (n = 178) for 1.85 
(0.04) years, and 3 (n = 98) for 1.63 (0.05) years. When 
expressed in relation to the treatment period, the reduc-
tion of adult height was 3.0 (0.1), 3.1 (0.1), and 2.9 (0.2) cm/
year of treatment, respectively. All the girls were treated 
with ethinyl estradiol as a daily single dose, while proges-
togen was given daily the first 10 days of every month. 
Hence 0.1 mg ethinyl estradiol daily for about 20 months 
was sufficient to reduce adult height. Here the recom-
mendation was made to start treatment at a bone matura-
tion of about 12 ‘years’  [3] – although with very tall girls 
one should begin earlier to achieve a worthwhile effect. 
 In an Australian study, adult height, compared to Bay-
ley-Pinneau predictions derived from the Greulich-Pyle 
Atlas, was underestimated by a mean of 1.86 ( 8 0.18) cm 
in the untreated group while the treated group ended up 
2.13 ( 8 0.2) cm below their pretreatment prediction. Mul-
tivariate regression showed that pretreatment skeletal 
maturity strongly predicted outcome. To remove bias in 
the height prediction model, a matched-pair analysis 
based on adult height prediction allowed 108 treated and 
untreated pairs to be matched. A treatment effect of 2.4 
cm (95% CI –3.2 to 1.8) reduction in adult height was de-
termined, and pretreatment BA again strongly predicted 
outcome, with a 6-cm reduction if treatment in girls com-
mences at BA 10, and a 1-cm reduction for each later BA 
‘year’ of commencement  [4] .
 In a retrospective study from Tübingen comprising a 
daily oral dose of 7.5 mg conjugated estrogens (plus 5 mg 
dydrogesterone for 10 days a month), the mean corrected 
effect of height-reducing therapy in girls was 3.6 cm 
(range: 11.9 to –3.3 cm) compared with untreated girls. 
Treatment was well tolerated  [2] . In boys, using 500 mg 
testosterone enanthate intramuscularly every 2 weeks  [2] , 
the mean corrected effect of height-reducing therapy was 
4.4 cm (range: 14.2 to –5.2 cm). Therapy was significant-
ly more effective when started at an earlier chronological 
age and BA, with only 1 cm benefit when starting at a BA 
of 13.5 in girls and 14.5 in boys – in line with Drop and 
colleagues  [5] who actually found a negative effect over 
predicted adult height in boys who began treatment with 
a BA of more than 14 ‘years’. There is as yet no consensus 
as to when treatment should be stopped: while Brämswig 
et al.  [6] advocated and still practice [J. Brämswig, pers. 
commun.] a treatment duration of 6 months only, others 
have recommended not to discontinue therapy before 
complete closure of the epiphyses of the hand has oc-
curred to avoid considerable posttreatment growth  [5] , 
and still others base stopping treatment on height veloc-
ity only. Recently, reports from Australia  [7] and the 
Netherlands  [8] indicated that estrogen treatment in ado-
lescence may be associated with an increased likelihood 
of fertility problems, which further discourages the use 
of estrogens for this indication. In men, androgen treat-
ment of tall stature does not seem to affect fatherhood or 
semen quality but serum testosterone levels are reduced 
 [9] . 
 In conclusion, the need for growth attenuation treat-
ment of adolescents with tall stature is limited and long-
term adverse effects have been reported so that treat-
ment is not recommended in most cases. However, pedi-
atric endocrinologists are regularly faced with patients 
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wanting a reduction of adult height and may still con-
sider this treatment or alternative treatments such as 
surgical epiphysiodesis in extreme cases. A BA assess-
ment is of invaluable help in assisting the decision-mak-
ing process. 
 Pubertal Disorders 
 The fundamental role of sex steroids in bone matura-
tion is obvious from the marked delay in skeletal matu-
rity of children with delayed puberty and its advance-
ment in children with PP. The effect of sex steroids over-
rides all other effects, so that bone maturation loses its 
relationship to a child’s calendar age during adolescence 
and correlates instead with the pubertal stages. Thus, the 
morphologic difference between a female BA of 12 and 13 
‘years’ is far greater than it is between a BA of 6 and 7 
‘years’. Since estrogen is the agent involved in maturation 
and closure of the epiphyseal plate in both genders  [10] , 
aromatase inhibitors can be used to slow bone matura-
tion. This has been shown to be of value in GnRH-inde-
pendent forms of PP such as testotoxicosis (familial male 
limited PP)  [11] or Peutz-Jeghers syndrome  [12] . Ran-
domized placebo-controlled studies using aromatase in-
hibitors in boys with pubertal delay  [13] , idiopathic short 
stature  [14, 15] or growth hormone deficiency  [16] have 
also shown an increase in predicted adult height, but its 
use in this and all other indications in pediatrics is off 
label and considered experimental. Further studies are 
needed to establish whether the adult height attained by 
some children with short stature can be improved by aro-
matase inhibitors and what role BA assessment can play 
in treatment decisions and monitoring in this context 
 [17–20] .
 Precocious Puberty 
 PP is most commonly defined as start of puberty 
 before the age of 9 years in boys and 8 years in girls. It 
 is usually subcategorized into central (gonadotropin-
dependent) and peripheral (gonadotropin-independent, 
pseudo-) PP. While the early onset of breast development 
in girls and genital development in boys is the essential 
criterion of PP, there are several other clinical features, 
such as increased growth velocity, increased skeletal mat-
uration, and uterine growth. The diagnosis of PP and its 
subcategories is based on physical examination, analysis 
of growth, assessment of bone maturation, ultrasound 
examination of the uterus and gonads, and hormone 
tests.
 Since in PP the premature exposure to sex hormones 
accelerates bone maturation, a skeletal maturity assess-
ment is part of the initial workup of every child with ear-
ly appearance of pubertal signs. The definition of rapid-
ly progressing PP encompasses rapid bone maturation 
( 1 2 SD for age), while in pubertal variants (precocious 
adrenarche, or premature thelarche) it is usually only 1–2 
SD above chronological age  [21] . Yet, when central PP is 
diagnosed early, there may be only a slight advance. 
 In some children, the progression of central PP may 
not be sustained or very slow, with bone growth and mat-
uration rates close to normal and with the preservation 
of predicted adult height. Hence, repeated bone matura-
tion monitoring instead of immediate initiation of treat-
ment is occasionally required and in some cases will serve 
to reassure the physician that treatment is not necessary. 
In girls older than 6 years of age at diagnosis of central 
PP, posttreatment acceleration of BA and early epiphy-
seal fusion compromise adult height potential  [22] . 
 Appropriate timing for discontinuation of GnRHa 
treatment of central PP is also related to bone maturation. 
It has been demonstrated that residual growth capacity
in treated children with central PP is optimal if GnRHa 
treatment is stopped at a BA of 12–12.5 ‘years’  [23–25] . 
However, bone maturation needs to be taken in context 
because a BA of approximately 12 ‘years’ can be observed 
at different chronological ages and because the height 
gain after treatment is dependent on the age at which 
treatment was started: only girls who are diagnosed with 
central PP and treated before the chronological age of 6 
years and stopped treatment at a BA of 12 ‘years’ reached 
the height predicted at the cessation of treatment and 
achieved target height  [22] . In practice, GnRH agonist 
treatment is often discontinued individually in concor-
dance with the pubertal development of the patient’s 
peers and the family history – with a little delay if one is 
trying to achieve maximum adult height.
 Sex steroids affect the short bones much more than the 
long bones or carpal bones  [26] . Thus, Vejvoda and Grant 
 [27] found that the short bones advanced faster than the 
carpal bones in 9 patients with PP. More recent results 
using the same Tübingen cohort as in Martin et al.  [28] 
support their statement and additionally show that car-
pals hardly respond to GnRH agonist treatment and thus 
catch up with the short bones (which respond to treat-
ment by showing no or very little maturation) during 
treatment. This implies that the carpals are less useful 
than the short bones for diagnosis or monitoring the 
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treatment of puberty disorders. Estrogen appears to have 
a stronger and faster influence on growth plates than on 
the appositional growth of the carpal bones  [28] . 
 Slowing of bone maturation contributes to improving 
adult height in central PP. Since the outer signs of puber-
ty, such as breast development or enlarged testes and pe-
nis, do not completely regress, bone maturation is an im-
portant monitoring instrument. Rapid bone maturation 
during treatment requires prompt reassessment of com-
pliance  [29] . 
 The most widely used methods of adult height predic-
tion are those of Bayley-Pinneau and Tanner-White-
house, which have yet to be validated in children with
PP. A systematic overestimation of adult height between 
4 and 13 cm was recorded in both untreated and treated 
girls  [30, 31] . In treated girls, the predictions of increased 
height given throughout the treatment period due to the 
deceleration of bone maturation proved to have been 
overly optimistic  [22] . BA is thus a useful diagnostic and 
monitoring tool for children with PP, provided that its 
limitations in clinical practice are recognized.
 Congenital Adrenal Hyperplasia 
 CAH is an autosomal recessive metabolic disease. In 
most forms, excess formation of androgens leads to viril-
ization of varying degree and (pseudo) PP. In other, rare, 
forms of CAH, formation of sex steroids is reduced or not 
possible; in these entities, bone maturation is typically 
delayed  [32] . The role of adrenal androgens – via local 
aromatization into estrogens – is well established for its 
rapid maturational impact on bone development in chil-
dren with CAH. The effect is greatest on the short bones 
(fingers and metacarpals), intermediate on the cuboid 
bones (carpals) and minimal on the long bones (radius 
and ulna) of the hand  [26] . 
 If left untreated, the overproduction of androgens in 
virilizing CAH usually leads to accelerated growth and 
bone maturation. Typically, the pattern of skeletal matu-
ration shows relative advancement of phalanges over car-
pals  [26, 33] . In untreated CAH, the growth pattern in 
early and mid childhood reveals tall stature but – due to 
premature closure of epiphyses – later results in short 
adult stature in most patients  [34–38] . However, it is in-
teresting to note that bone maturation in untreated viril-
izing CAH does not occur during the first 2 years of life 
 [26, 39, 40] .
 Attainment of normal adult stature is one of the pri-
mary goals in the treatment of CAH. This primarily con-
sists of providing the patient with enough glucocorticoids 
and, if necessary, mineralocorticoids to suppress ACTH-
mediated excess androgen production – monitored by 
regular measurement of diagnostically important key 
hormones or metabolites, height, weight and bone matu-
ration. Finding the correct dosage poses a special chal-
lenge because even slight overdoses of glucocorticoids will 
curb growth and bone maturation  [36, 38, 41–43] . A meta-
analysis of 18 studies carried out from 1977 to 1997 found 
a mean adult height following glucocorticoid treatment of 
–1.37 SDS below the respective population mean  [41] . 
 Thus, assessing bone maturation is useful both in the 
diagnostic evaluation of suspected CAH as well as in the 
monitoring of treatment of children with CAH  [44] . For 
optimal control, height and weight should be measured 
every 3 months and bone maturation at least yearly.
 Skeletal Dysplasia 
 Skeletal dysplasias are a heterogeneous group of disor-
ders mainly affecting the skeleton; the estimated overall 
incidence is 1 case in 4,000–5,000 births. Almost all lead 
to moderate to severe short stature, usually dispropor-
tionate. Achondroplasia is one of the more frequent dis-
orders (1 in 25,000 births). The mean adult height with 
this disorder is around 131 cm for men and 124 cm for 
women. BA determination in children with skeletal dys-
plasia is only possible in a few disorders and estimations 
should be treated with caution. Radiographs of the left 
hand are, on the other hand, part of the skeletal survey 
and essential in the diagnosis of many skeletal disorders. 
It is of importance to note that the diagnosis of a skeletal 
dysplasia can be very difficult – and in many cases as yet 
impossible – and usually requires close collaboration be-
tween the pediatrician, clinical geneticist and pediatric 
radiologist. A full radiologic skeletal survey is indicated 
in all patients with disproportionate short stature, as re-
cently reviewed  [45] .
 BA and the Evaluation of Bone Mineral Mass and 
Density 
 It is now well known in bone densitometry that Z scores 
instead of T scores need to be used in children  [46, 47] . The 
problem of the Z score lies in the fact that it compares the 
patient with a group of children with the same chrono-
logical age which does not necessarily reflect the height or 
maturity of the individual. Though reference values for 
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bone mineral density against bone maturation are not yet 
available, in bone densitometry the use of bone matura-
tion makes sense  [48] . To avoid errors when interpreting 
the bone mineral mass or density, muscle mass or force 
 [49] , as well as height and BA need to be taken into con-
sideration. 
 Estimating Chronological Age when the Date of 
Birth Is Unknown 
 Pediatricians are sometimes put in the uncomfortable 
position of being asked to estimate the chronological age 
of a child for immigration authorities or the criminal 
courts. Automated BA reading may contribute to the 
standardization of BA estimation but will not solve the 
problem that precisely those children for which such tests 
are needed have a very mixed (and often disadvantaged) 
socioeconomic, ethnic, genetic, and nutritional back-
ground – all factors which may have an impact on BA 
 [50] . There are as yet no models developed on the basis of 
these parameters in the relevant populations. Given the 
lack of evidence and the socioeconomic impact of this 
(nonmedical) evaluation, providing an age estimate to 
immigration authorities or the criminal courts has no 
scientific foundation and should be avoided  [51–53] . 
 BA and Secular Trends in Growth and Pubertal 
Development 
 Evidence for a secular trend in the reduction of the age 
at which various milestones of puberty are reached is very 
variable from region to region. The age at menarche had 
consistently fallen over the 20th century, but there is a 
suggestion of a slowdown in the age decline in more 
northern Europeans, hence by inference that a minimum 
age has been reached  [54] . More detailed records of puber-
tal staging shows much variation. The US-wide observa-
tions from national studies and individual records by lo-
cal pediatricians note a fall in the age of onset of puberty, 
but not such similar reductions in ages at pubertal com-
pletion, implying that the pubertal process is becoming 
prolonged in the current generation  [55] . This finding has 
also been observed in a historic and a contemporary Dan-
ish cohort of children followed longitudinally  [56, 57] . An 
increased size of the current generation was noted but the 
gain in weight was not sufficient to fully explain the trend. 
These findings are not evident in less socially advantaged 
populations such as in Russian Chapaevsk boys  [58] .
 What effect therefore is seen on the rate of BA matura-
tion? Urban Chinese children from Beijing are showing 
earlier skeletal maturation with a significantly earlier 
peak in BA acceleration than the TW3 standards and, in 
comparison with rural Chinese, adult status is achieved 
2 years sooner  [59] . The pattern of maturation in the Bei-
jing children matches that of those from the Japanese 
capital Tokyo. A similar trend towards earlier maturity 
was seen in the Madeira growth study  [60] . The matura-
tion of the radius, ulna and short bones proceeded earlier 
in boys, but both sexes demonstrated a 2-year advance of 
the age of peak skeletal maturity velocity. Interestingly, 
this trend was only slightly apparent for the carpal bones. 
Part of the variations in the extent of the advance in skel-
etal maturity status may be attributable to the method of 
BA estimation. In a comparison of two systems, the TW3 
method resulted in a more advanced BA estimation on 
the same film compared with the Fels method  [61] , while 
the older TW2 system may significantly underestimate 
skeletal maturity  [62] .
 There is thus mixed evidence of a secular trend in 
 pubertal development together with an alteration in the 
onset and also in the tempo of puberty. This secular
trend also appears to be present in skeletal maturation. 
Increased size of contemporary children is only one asso-
ciated parameter; it is unclear whether there is a direct 
effect of obesity per se on the advance of puberty and 
 skeletal maturity in the affluent part of the world. Impli-
cations of this trend and the readjustment of observed 
population changes within pathological conditions need 
further study.
 Conclusion 
 In part 2 of this review on the use of bone maturation 
in clinical practice, we have examined the role of BA as-
sessment in modern pediatric management of tall stature, 
PP and CAH, and discussed secular trend. While manu-
al bone maturation rating is the main tool used in these 
conditions, more recent automated techniques may pro-
vide advances in this field and facilitate international 
studies and standardization.
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